Testing a short radiation schedule with internal boost for prostate cancer
Tests a short radiation course with an internal boost in men with prostate cancer.
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Registry title
- Evaluating Tolerability of ePUHRT With Brachytherapy Boost
- Status
- Recruiting
- People taking part
- 31 people, planned
- Started
- 5 Mar 2025
- Expected to end
- Oct 2028
- Type of study
- Interventional
- Treatments tested
- ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
- Record updated
- 2 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer of unfavorable intermediate, high or very high risk who plan to have a high dose brachytherapy boost as standard care.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Pathologically confirmed unfavorable intermediate, high or very high-risk prostate cancer. No signs of nodal or distant disease.
- Earlier treatment
- No earlier radiation to the pelvis. No earlier prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate.
Main reasons for not taking part
- Prior pelvic irradiation treatment
- Prior rectal surgery that rules out a rectal ultrasound probe
- Signs of nodal or distant disease on screening tests
- Prior prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate
- International Prostate Symptom Score (IPSS) above 16 despite medical therapy
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- ≥ 18 years old at the time of informed consent
- Capable of providing informed consent and HIPAA authorization
- Karnofsky performance score ≥ 70
- Pathologically confirmed unfavorable intermediate, high, and very high-risk prostate cancer per treating physician
- Candidate plans to undergo the standard of care prostate high dose brachytherapy boost procedure
Who cannot take part
- Prior pelvic irradiation treatment
- Prior rectal surgery which precludes instrumentation with rectal ultrasound probe
- Prior prostatectomy, Holmium laser enucleation of the prostate or transurethral resection of the prostate procedure
- International Prostate Symptom Score (IPSS) score > 16 despite medical therapy
- Evidence of nodal or distant disease on screening diagnostic work up
Where in United States
- Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolis, United StatesContact: Kathy LauerTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the tolerability and toxicity of combining two radiation therapy methods for prostate cancer: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is an external beam radiotherapy with High Dose Rate Brachytherapy Boost (form of internal radiation where a cancer doctor implants a small plastic tube or balloon (catheter) in the tumor).
The group in the trial
- ePURT 5Gy x 5 fractions with single HDR boost of 15GyTreatment being tested
Single arm non-randomized non-inferiority study exploring tolerability of ePURT 5Gy x 5 fractions delivered on noncontiguous weekdays with single HDR boost of 15Gy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluating Tolerability of Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT) With High Dose Rate Brachytherapy Boost for Unfavorable and Higher Risk Prostate Cancer
- Plain-language title
- Testing a short radiation schedule with internal boost for prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 November 2026